This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-155-5p | ABI2 | 0.71 | 0.00687 | 0.18 | 0.14787 | mirMAP | -0.23 | 0 | NA | |
2 | hsa-miR-155-5p | ABL2 | 0.71 | 0.00687 | 0.82 | 0 | mirMAP | -0.11 | 1.0E-5 | NA | |
3 | hsa-miR-155-5p | ACADSB | 0.71 | 0.00687 | -0.98 | 0 | mirMAP | -0.13 | 0.00018 | NA | |
4 | hsa-miR-155-5p | ACTA1 | 0.71 | 0.00687 | -0.34 | 0.3688 | MirTarget; miRNATAP | -0.45 | 0 | NA | |
5 | hsa-miR-155-5p | ACVR2A | 0.71 | 0.00687 | -0.41 | 0.00039 | miRNATAP | -0.15 | 0 | NA | |
6 | hsa-miR-155-5p | ADH5 | 0.71 | 0.00687 | -0.37 | 0.00013 | miRNAWalker2 validate | -0.1 | 0 | NA | |
7 | hsa-miR-155-5p | AGL | 0.71 | 0.00687 | -0.17 | 0.16618 | miRNAWalker2 validate | -0.13 | 1.0E-5 | NA | |
8 | hsa-miR-155-5p | AGTR1 | 0.71 | 0.00687 | -2.47 | 0 | miRNAWalker2 validate; miRTarBase | -0.76 | 0 | 22525818 | MicroRNA-155 miR-155 is one of the micro RNAs miRNA most consistently involved in neoplastic diseases and it is known to repress the angiotensin II type 1 receptor AGTR1; The aim of the present study was to evaluate the expressions of miR-155 and AGTR1 and to clarify the potential efficacy of anti-miR-155 alone and in combination with AGTR1 blocker losartan in endometrial cancers; Expressions of miR-155 and AGTR1 were evaluated using real-time PCR and immunohistochemistry; miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues; We checked that abolishing the function of miR-155 and AGTR1 by anti-miR-155 or losartan inhibited cell survival of endometrial carcinoma cells respectively and furthermore combined treatment showed synergistic effects; In this study we characterized the expressions of miR-155 and AGTR1 in endometrial tissues; The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer |
9 | hsa-miR-155-5p | ALDH1A2 | 0.71 | 0.00687 | -2.41 | 0 | miRNAWalker2 validate | -0.47 | 0 | NA | |
10 | hsa-miR-155-5p | AMIGO2 | 0.71 | 0.00687 | 0.61 | 0.01903 | miRNAWalker2 validate | -0.2 | 0.00101 | NA | |
11 | hsa-miR-155-5p | ANAPC16 | 0.71 | 0.00687 | -0.56 | 0 | miRNAWalker2 validate | -0.12 | 0 | NA | |
12 | hsa-miR-155-5p | ANKH | 0.71 | 0.00687 | 0.46 | 0.00392 | mirMAP | -0.16 | 1.0E-5 | NA | |
13 | hsa-miR-155-5p | ANO5 | 0.71 | 0.00687 | -2.17 | 0 | MirTarget | -0.64 | 0 | NA | |
14 | hsa-miR-155-5p | ANTXR1 | 0.71 | 0.00687 | 0.82 | 0.00014 | miRNAWalker2 validate | -0.24 | 0 | NA | |
15 | hsa-miR-155-5p | ANTXR2 | 0.71 | 0.00687 | -0.73 | 0.00186 | MirTarget; miRNATAP | -0.33 | 0 | NA | |
16 | hsa-miR-155-5p | AR | 0.71 | 0.00687 | -1.55 | 0 | mirMAP | -0.56 | 0 | NA | |
17 | hsa-miR-155-5p | ARHGAP5 | 0.71 | 0.00687 | -0.12 | 0.26304 | mirMAP | -0.18 | 0 | NA | |
18 | hsa-miR-155-5p | ARL10 | 0.71 | 0.00687 | -0.28 | 0.19832 | miRNAWalker2 validate | -0.31 | 0 | NA | |
19 | hsa-miR-155-5p | ARL8B | 0.71 | 0.00687 | -0.21 | 0.01117 | miRNAWalker2 validate | -0.11 | 0 | NA | |
20 | hsa-miR-155-5p | ARMC2 | 0.71 | 0.00687 | 0.21 | 0.09317 | miRNAWalker2 validate | -0.14 | 0 | NA | |
21 | hsa-miR-155-5p | ATF7 | 0.71 | 0.00687 | 0.07 | 0.43806 | mirMAP | -0.15 | 0 | NA | |
22 | hsa-miR-155-5p | ATL2 | 0.71 | 0.00687 | -0.38 | 0.00058 | miRNAWalker2 validate | -0.21 | 0 | NA | |
23 | hsa-miR-155-5p | ATRNL1 | 0.71 | 0.00687 | -1.69 | 1.0E-5 | MirTarget; mirMAP | -0.57 | 0 | NA | |
24 | hsa-miR-155-5p | AXL | 0.71 | 0.00687 | -0.19 | 0.3511 | miRNAWalker2 validate | -0.16 | 0.00064 | NA | |
25 | hsa-miR-155-5p | BCL6 | 0.71 | 0.00687 | -0.21 | 0.19489 | miRNAWalker2 validate; miRTarBase | -0.19 | 0 | 23169640 | We show that Bcl6 is indirectly regulated by miR-155 through Mxd1/Mad1 up-regulation; Interestingly we found that miR-155 directly targets HDAC4 a corepressor partner of BCL6; Meta-analysis of the diffuse large B-cell lymphoma patient microarray data showed that miR-155 expression is inversely correlated with Bcl6 and Hdac4; Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias |
26 | hsa-miR-155-5p | BCORL1 | 0.71 | 0.00687 | 0.35 | 0.01214 | MirTarget | -0.18 | 0 | NA | |
27 | hsa-miR-155-5p | BNC2 | 0.71 | 0.00687 | -0.49 | 0.09988 | MirTarget | -0.38 | 0 | NA | |
28 | hsa-miR-155-5p | BNIP2 | 0.71 | 0.00687 | -0.05 | 0.63907 | mirMAP | -0.16 | 0 | NA | |
29 | hsa-miR-155-5p | BOC | 0.71 | 0.00687 | -0.91 | 0.0056 | MirTarget | -0.44 | 0 | NA | |
30 | hsa-miR-155-5p | BRWD1 | 0.71 | 0.00687 | 0.05 | 0.6598 | mirMAP | -0.15 | 0 | NA | |
31 | hsa-miR-155-5p | C3orf18 | 0.71 | 0.00687 | -1.27 | 0 | miRNATAP | -0.28 | 0 | NA | |
32 | hsa-miR-155-5p | CA5B | 0.71 | 0.00687 | -0.07 | 0.65344 | mirMAP | -0.21 | 0 | NA | |
33 | hsa-miR-155-5p | CAB39L | 0.71 | 0.00687 | -1.77 | 0 | miRNAWalker2 validate | -0.55 | 0 | NA | |
34 | hsa-miR-155-5p | CACNA2D1 | 0.71 | 0.00687 | -0.85 | 0.00675 | mirMAP | -0.45 | 0 | NA | |
35 | hsa-miR-155-5p | CACNB4 | 0.71 | 0.00687 | -1.06 | 0.0002 | mirMAP; miRNATAP | -0.28 | 2.0E-5 | NA | |
36 | hsa-miR-155-5p | CADM2 | 0.71 | 0.00687 | -3.78 | 0 | mirMAP | -0.81 | 0 | NA | |
37 | hsa-miR-155-5p | CALU | 0.71 | 0.00687 | 0.67 | 0 | miRNAWalker2 validate | -0.1 | 6.0E-5 | NA | |
38 | hsa-miR-155-5p | CAMTA1 | 0.71 | 0.00687 | -0.44 | 1.0E-5 | miRNAWalker2 validate; MirTarget | -0.11 | 0 | NA | |
39 | hsa-miR-155-5p | CBR4 | 0.71 | 0.00687 | -0.32 | 0.00664 | miRNAWalker2 validate | -0.16 | 0 | NA | |
40 | hsa-miR-155-5p | CBX5 | 0.71 | 0.00687 | 0.16 | 0.24446 | mirMAP | -0.15 | 0 | NA | |
41 | hsa-miR-155-5p | CCDC82 | 0.71 | 0.00687 | 0.34 | 0.00084 | miRNAWalker2 validate | -0.12 | 0 | NA | |
42 | hsa-miR-155-5p | CD109 | 0.71 | 0.00687 | 0.26 | 0.3195 | miRNAWalker2 validate | -0.38 | 0 | NA | |
43 | hsa-miR-155-5p | CDH13 | 0.71 | 0.00687 | 0.63 | 0.00094 | miRNAWalker2 validate | -0.22 | 0 | NA | |
44 | hsa-miR-155-5p | CDH2 | 0.71 | 0.00687 | -0.68 | 0.04042 | miRNAWalker2 validate | -0.3 | 7.0E-5 | NA | |
45 | hsa-miR-155-5p | CDH6 | 0.71 | 0.00687 | 0.84 | 0 | miRNAWalker2 validate | -0.21 | 0 | NA | |
46 | hsa-miR-155-5p | CELF2 | 0.71 | 0.00687 | -1.1 | 1.0E-5 | miRNATAP | -0.12 | 0.04671 | NA | |
47 | hsa-miR-155-5p | CEP68 | 0.71 | 0.00687 | -0.36 | 0.00246 | MirTarget | -0.22 | 0 | NA | |
48 | hsa-miR-155-5p | CFL2 | 0.71 | 0.00687 | -1.3 | 0 | miRNAWalker2 validate | -0.51 | 0 | NA | |
49 | hsa-miR-155-5p | CHD9 | 0.71 | 0.00687 | -0.26 | 0.02092 | miRNAWalker2 validate | -0.13 | 0 | NA | |
50 | hsa-miR-155-5p | CHST9 | 0.71 | 0.00687 | -3.2 | 0 | miRNATAP | -0.67 | 0 | NA | |
51 | hsa-miR-155-5p | CLIC4 | 0.71 | 0.00687 | -0.39 | 0.04124 | miRNAWalker2 validate | -0.33 | 0 | NA | |
52 | hsa-miR-155-5p | CNTN3 | 0.71 | 0.00687 | -2.46 | 0 | MirTarget | -0.44 | 1.0E-5 | NA | |
53 | hsa-miR-155-5p | CNTN4 | 0.71 | 0.00687 | -0.83 | 0.00133 | miRNATAP | -0.27 | 1.0E-5 | NA | |
54 | hsa-miR-155-5p | COL4A2 | 0.71 | 0.00687 | 1.02 | 0 | miRNAWalker2 validate | -0.2 | 1.0E-5 | NA | |
55 | hsa-miR-155-5p | CPEB4 | 0.71 | 0.00687 | -0.8 | 0 | mirMAP | -0.17 | 0 | NA | |
56 | hsa-miR-155-5p | CRAT | 0.71 | 0.00687 | -0.93 | 1.0E-5 | miRNAWalker2 validate | -0.15 | 0.00135 | NA | |
57 | hsa-miR-155-5p | CREBRF | 0.71 | 0.00687 | -0.37 | 0.00727 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.19 | 0 | NA | |
58 | hsa-miR-155-5p | CUL4B | 0.71 | 0.00687 | 0.16 | 0.10357 | miRNAWalker2 validate | -0.14 | 0 | NA | |
59 | hsa-miR-155-5p | CUX1 | 0.71 | 0.00687 | -0.04 | 0.6705 | miRNAWalker2 validate | -0.11 | 0 | NA | |
60 | hsa-miR-155-5p | CYP2U1 | 0.71 | 0.00687 | -0.7 | 0.00028 | miRNAWalker2 validate | -0.22 | 0 | NA | |
61 | hsa-miR-155-5p | CYR61 | 0.71 | 0.00687 | -0.31 | 0.22652 | miRNAWalker2 validate; miRTarBase | -0.15 | 0.01455 | NA | |
62 | hsa-miR-155-5p | DACH2 | 0.71 | 0.00687 | -1.63 | 0.00034 | mirMAP | -0.39 | 0.00024 | NA | |
63 | hsa-miR-155-5p | DBN1 | 0.71 | 0.00687 | -0.23 | 0.22787 | miRNAWalker2 validate | -0.22 | 0 | NA | |
64 | hsa-miR-155-5p | DCAF10 | 0.71 | 0.00687 | -0.03 | 0.75108 | mirMAP | -0.12 | 0 | NA | |
65 | hsa-miR-155-5p | DCUN1D2 | 0.71 | 0.00687 | 0.17 | 0.12271 | miRNAWalker2 validate | -0.18 | 0 | NA | |
66 | hsa-miR-155-5p | DCUN1D4 | 0.71 | 0.00687 | -0.26 | 0.02159 | miRNATAP | -0.19 | 0 | NA | |
67 | hsa-miR-155-5p | DGKG | 0.71 | 0.00687 | -1.63 | 0 | mirMAP | -0.46 | 0 | NA | |
68 | hsa-miR-155-5p | DIXDC1 | 0.71 | 0.00687 | -1.16 | 0 | MirTarget | -0.48 | 0 | NA | |
69 | hsa-miR-155-5p | DMD | 0.71 | 0.00687 | -1.51 | 0 | miRNAWalker2 validate | -0.66 | 0 | NA | |
70 | hsa-miR-155-5p | DOCK4 | 0.71 | 0.00687 | 0.5 | 0.00108 | miRNAWalker2 validate | -0.11 | 0.00163 | NA | |
71 | hsa-miR-155-5p | DPP8 | 0.71 | 0.00687 | -0.01 | 0.89537 | mirMAP | -0.11 | 0 | NA | |
72 | hsa-miR-155-5p | DYNC1I1 | 0.71 | 0.00687 | -1.12 | 0.00107 | MirTarget; miRNATAP | -0.64 | 0 | NA | |
73 | hsa-miR-155-5p | DYNC2H1 | 0.71 | 0.00687 | -0.56 | 0.01731 | miRNAWalker2 validate | -0.39 | 0 | NA | |
74 | hsa-miR-155-5p | EBF1 | 0.71 | 0.00687 | -0.38 | 0.08856 | miRNATAP | -0.17 | 0.00122 | NA | |
75 | hsa-miR-155-5p | EBF2 | 0.71 | 0.00687 | 1.63 | 0 | mirMAP | -0.46 | 0 | NA | |
76 | hsa-miR-155-5p | EBF3 | 0.71 | 0.00687 | -0.06 | 0.81437 | mirMAP | -0.23 | 4.0E-5 | NA | |
77 | hsa-miR-155-5p | EEF1A2 | 0.71 | 0.00687 | -3.58 | 0 | miRNAWalker2 validate | -0.47 | 0.00052 | NA | |
78 | hsa-miR-155-5p | EGFR | 0.71 | 0.00687 | -0.17 | 0.48451 | miRNAWalker2 validate; MirTarget | -0.14 | 0.01476 | NA | |
79 | hsa-miR-155-5p | EIF4E3 | 0.71 | 0.00687 | -1.24 | 0 | mirMAP | -0.2 | 0 | NA | |
80 | hsa-miR-155-5p | ENTPD3 | 0.71 | 0.00687 | -2.57 | 0 | MirTarget | -0.48 | 0 | NA | |
81 | hsa-miR-155-5p | EPHA5 | 0.71 | 0.00687 | -0.96 | 0.01733 | mirMAP | -0.53 | 0 | NA | |
82 | hsa-miR-155-5p | ERBB4 | 0.71 | 0.00687 | -1.97 | 2.0E-5 | mirMAP | -0.44 | 4.0E-5 | NA | |
83 | hsa-miR-155-5p | ETNK2 | 0.71 | 0.00687 | -0.69 | 0.03013 | miRNATAP | -0.49 | 0 | NA | |
84 | hsa-miR-155-5p | ETV1 | 0.71 | 0.00687 | -0.1 | 0.67674 | mirMAP | -0.33 | 0 | NA | |
85 | hsa-miR-155-5p | FADS1 | 0.71 | 0.00687 | 0.27 | 0.2134 | miRNAWalker2 validate | -0.18 | 0.00028 | NA | |
86 | hsa-miR-155-5p | FAM114A1 | 0.71 | 0.00687 | -0.46 | 0.0001 | mirMAP | -0.1 | 0.00014 | NA | |
87 | hsa-miR-155-5p | FAM168A | 0.71 | 0.00687 | -0.19 | 0.12893 | MirTarget | -0.13 | 1.0E-5 | NA | |
88 | hsa-miR-155-5p | FAM20B | 0.71 | 0.00687 | 0.01 | 0.91599 | mirMAP | -0.22 | 0 | NA | |
89 | hsa-miR-155-5p | FAM212B | 0.71 | 0.00687 | -1 | 0 | MirTarget; miRNATAP | -0.34 | 0 | NA | |
90 | hsa-miR-155-5p | FAM8A1 | 0.71 | 0.00687 | -0.22 | 0.02652 | mirMAP | -0.16 | 0 | NA | |
91 | hsa-miR-155-5p | FBXL2 | 0.71 | 0.00687 | -0.04 | 0.8586 | MirTarget | -0.39 | 0 | NA | |
92 | hsa-miR-155-5p | FGF2 | 0.71 | 0.00687 | -1.03 | 2.0E-5 | miRNAWalker2 validate; mirMAP | -0.38 | 0 | NA | |
93 | hsa-miR-155-5p | FGF5 | 0.71 | 0.00687 | 0.55 | 0.28659 | mirMAP | -0.74 | 0 | NA | |
94 | hsa-miR-155-5p | FGF7 | 0.71 | 0.00687 | -0.41 | 0.18581 | miRNAWalker2 validate; miRTarBase; mirMAP; miRNATAP | -0.33 | 1.0E-5 | NA | |
95 | hsa-miR-155-5p | FGF9 | 0.71 | 0.00687 | -0.57 | 0.17095 | miRNATAP | -0.32 | 0.00074 | NA | |
96 | hsa-miR-155-5p | FIGN | 0.71 | 0.00687 | -0.9 | 0.00585 | mirMAP | -0.28 | 0.00024 | NA | |
97 | hsa-miR-155-5p | FKBP14 | 0.71 | 0.00687 | 0.49 | 8.0E-5 | mirMAP | -0.17 | 0 | NA | |
98 | hsa-miR-155-5p | FKBP5 | 0.71 | 0.00687 | -0.94 | 1.0E-5 | mirMAP | -0.13 | 0.00864 | NA | |
99 | hsa-miR-155-5p | FLNA | 0.71 | 0.00687 | -0.77 | 0.01377 | miRNAWalker2 validate | -0.52 | 0 | NA | |
100 | hsa-miR-155-5p | FLRT2 | 0.71 | 0.00687 | -0.05 | 0.86608 | mirMAP | -0.22 | 0.0013 | NA | |
101 | hsa-miR-155-5p | FMO2 | 0.71 | 0.00687 | -0.97 | 0.01987 | mirMAP | -0.21 | 0.03467 | NA | |
102 | hsa-miR-155-5p | FOXK1 | 0.71 | 0.00687 | 0.73 | 0 | miRNAWalker2 validate; miRNATAP | -0.13 | 5.0E-5 | NA | |
103 | hsa-miR-155-5p | FOXO3 | 0.71 | 0.00687 | -0.04 | 0.72028 | miRNAWalker2 validate; miRTarBase | -0.15 | 0 | 27596294; 25480585; 20371610; 26398931; 22027557; 27107135 | MiR-155 targets 3´UTR region of multiple components of the pro-oncogenic signaling cascades including FOXO3a tumor suppressor and RUNX2 transcription factor regulating metastatic potential in BC;The effect of miRNA155 on FOXO3a expression was examined by Western blotting; FOXO3a was found to be a possible target of miRNA155 as suggested by Targetscan website;MicroRNA 155 regulates cell survival growth and chemosensitivity by targeting FOXO3a in breast cancer; In this study we demonstrate the critical role of miR-155 in regulation of cell survival and chemosensitivity through down-regulation of FOXO3a in breast cancer; Further we identified FOXO3a as a direct target of miR-155; Sustained overexpression of miR-155 resulted in repression of FOXO3a protein without changing mRNA levels and knockdown of miR-155 increases FOXO3a; Finally inverse correlation between miR-155 and FOXO3a levels were observed in a panel of breast cancer cell lines and tumors; In conclusion our study reveals a molecular link between miR-155 and FOXO3a and presents evidence that miR-155 is a critical therapeutic target in breast cancer;In contrast downregulation of miR-155-5p increased sensitivity to bufalin and upregulated the expression of FOXO3A;Here we show that hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated target FOXO3A;Our results further revealed that forkhead box O3a FoxO3a was a miR-155 target in the heart; And miR-155 directly repressed FoxO3a whose expression was mitigated in miR-155 agomir and mimic treatment in vivo and in vitro |
104 | hsa-miR-155-5p | FSTL1 | 0.71 | 0.00687 | 0.59 | 0.00382 | miRNAWalker2 validate | -0.22 | 0 | NA | |
105 | hsa-miR-155-5p | FUBP3 | 0.71 | 0.00687 | 0.16 | 0.02317 | miRNAWalker2 validate | -0.11 | 0 | NA | |
106 | hsa-miR-155-5p | FZD3 | 0.71 | 0.00687 | 0.1 | 0.60316 | mirMAP | -0.3 | 0 | NA | |
107 | hsa-miR-155-5p | GABARAPL1 | 0.71 | 0.00687 | -1.2 | 0 | miRNAWalker2 validate | -0.19 | 1.0E-5 | NA | |
108 | hsa-miR-155-5p | GABRB2 | 0.71 | 0.00687 | -1.84 | 0.00029 | mirMAP | -0.52 | 1.0E-5 | NA | |
109 | hsa-miR-155-5p | GAPVD1 | 0.71 | 0.00687 | 0.2 | 0.02872 | miRNAWalker2 validate | -0.11 | 0 | NA | |
110 | hsa-miR-155-5p | GCFC2 | 0.71 | 0.00687 | 0.27 | 0.0082 | miRNAWalker2 validate | -0.12 | 0 | NA | |
111 | hsa-miR-155-5p | GFRA1 | 0.71 | 0.00687 | -3.07 | 0 | mirMAP | -0.53 | 1.0E-5 | NA | |
112 | hsa-miR-155-5p | GNB4 | 0.71 | 0.00687 | -0.06 | 0.76083 | miRNAWalker2 validate | -0.19 | 5.0E-5 | NA | |
113 | hsa-miR-155-5p | GPAM | 0.71 | 0.00687 | 0.14 | 0.29732 | miRNAWalker2 validate | -0.16 | 0 | NA | |
114 | hsa-miR-155-5p | GPM6B | 0.71 | 0.00687 | -2.16 | 0 | miRNAWalker2 validate; MirTarget | -0.57 | 0 | NA | |
115 | hsa-miR-155-5p | GRIP1 | 0.71 | 0.00687 | -0.82 | 0.0011 | miRNATAP | -0.35 | 0 | NA | |
116 | hsa-miR-155-5p | GYG1 | 0.71 | 0.00687 | -0.45 | 0.00051 | MirTarget | -0.18 | 0 | NA | |
117 | hsa-miR-155-5p | HBP1 | 0.71 | 0.00687 | -0.45 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.11 | 0 | 25666090 | miR 155 promotes the growth of osteosarcoma in a HBP1 dependent mechanism; HMG-box transcription factor 1 HBP1 a strong Wnt pathway suppressor was found to be a target of miR-155; Restoration of HBP1 abolished the effect of miR-155 on OS cells |
118 | hsa-miR-155-5p | HECA | 0.71 | 0.00687 | -0.22 | 0.03463 | MirTarget | -0.13 | 0 | NA | |
119 | hsa-miR-155-5p | HIVEP2 | 0.71 | 0.00687 | -0 | 0.99823 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.16 | 0 | NA | |
120 | hsa-miR-155-5p | HSDL1 | 0.71 | 0.00687 | 0.15 | 0.16056 | miRNAWalker2 validate | -0.14 | 0 | NA | |
121 | hsa-miR-155-5p | HSPA4L | 0.71 | 0.00687 | -0.1 | 0.744 | miRNAWalker2 validate | -0.15 | 0.03154 | NA | |
122 | hsa-miR-155-5p | HTRA1 | 0.71 | 0.00687 | 0.21 | 0.25867 | miRNAWalker2 validate | -0.15 | 0.00083 | NA | |
123 | hsa-miR-155-5p | HUNK | 0.71 | 0.00687 | 0.47 | 0.10393 | mirMAP | -0.19 | 0.00464 | NA | |
124 | hsa-miR-155-5p | IGF1 | 0.71 | 0.00687 | -0.2 | 0.5898 | mirMAP | -0.28 | 0.0012 | NA | |
125 | hsa-miR-155-5p | IGF1R | 0.71 | 0.00687 | 0.12 | 0.57112 | mirMAP | -0.13 | 0.00801 | NA | |
126 | hsa-miR-155-5p | IL13RA1 | 0.71 | 0.00687 | 0.02 | 0.86949 | miRNAWalker2 validate; miRTarBase | -0.15 | 0 | NA | |
127 | hsa-miR-155-5p | IL17RD | 0.71 | 0.00687 | -0.02 | 0.94873 | mirMAP | -0.63 | 0 | NA | |
128 | hsa-miR-155-5p | IL6ST | 0.71 | 0.00687 | -0.4 | 0.00676 | mirMAP | -0.15 | 1.0E-5 | NA | |
129 | hsa-miR-155-5p | IMPAD1 | 0.71 | 0.00687 | 0.29 | 0.0008 | miRNAWalker2 validate | -0.12 | 0 | NA | |
130 | hsa-miR-155-5p | INA | 0.71 | 0.00687 | -2.51 | 0 | miRNAWalker2 validate | -0.5 | 0 | NA | |
131 | hsa-miR-155-5p | INPP5F | 0.71 | 0.00687 | 0.05 | 0.70327 | miRNAWalker2 validate | -0.2 | 0 | NA | |
132 | hsa-miR-155-5p | IRF2BP2 | 0.71 | 0.00687 | 0.35 | 7.0E-5 | MirTarget; miRNATAP | -0.13 | 0 | NA | |
133 | hsa-miR-155-5p | ITGB5 | 0.71 | 0.00687 | 0.36 | 0.00664 | miRNAWalker2 validate | -0.11 | 0.00016 | NA | |
134 | hsa-miR-155-5p | JUN | 0.71 | 0.00687 | -0.93 | 0 | miRNAWalker2 validate; miRTarBase | -0.18 | 0 | 23693020 | In the present study we demonstrated for the first time that activation of RAGE by S100P regulates oncogenic microRNA-155 miR-155 expression through Activator Protein-1 AP-1 stimulation in colon cancer cells |
135 | hsa-miR-155-5p | KANK2 | 0.71 | 0.00687 | -0.93 | 2.0E-5 | miRNAWalker2 validate | -0.43 | 0 | NA | |
136 | hsa-miR-155-5p | KANSL1 | 0.71 | 0.00687 | 0.25 | 0.00277 | miRNATAP | -0.1 | 0 | NA | |
137 | hsa-miR-155-5p | KANSL1L | 0.71 | 0.00687 | 0.26 | 0.01018 | MirTarget | -0.13 | 0 | NA | |
138 | hsa-miR-155-5p | KCNA1 | 0.71 | 0.00687 | -2.36 | 0.00043 | mirMAP; miRNATAP | -0.77 | 0 | NA | |
139 | hsa-miR-155-5p | KCND3 | 0.71 | 0.00687 | -1.25 | 9.0E-5 | mirMAP | -0.22 | 0.00273 | NA | |
140 | hsa-miR-155-5p | KDELC1 | 0.71 | 0.00687 | 0.95 | 0 | miRNAWalker2 validate | -0.1 | 0.00292 | NA | |
141 | hsa-miR-155-5p | KDELC2 | 0.71 | 0.00687 | 0.22 | 0.08988 | miRNAWalker2 validate | -0.15 | 0 | NA | |
142 | hsa-miR-155-5p | KDM3A | 0.71 | 0.00687 | 0.13 | 0.22711 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.13 | 0 | NA | |
143 | hsa-miR-155-5p | KDM5B | 0.71 | 0.00687 | 0.27 | 0.01491 | MirTarget | -0.14 | 0 | NA | |
144 | hsa-miR-155-5p | KIAA0430 | 0.71 | 0.00687 | -0.3 | 0.00341 | miRNAWalker2 validate | -0.11 | 0 | NA | |
145 | hsa-miR-155-5p | KIAA1462 | 0.71 | 0.00687 | 0.55 | 0.00405 | MirTarget | -0.11 | 0.01864 | NA | |
146 | hsa-miR-155-5p | KIAA2022 | 0.71 | 0.00687 | -2.81 | 0 | mirMAP | -0.72 | 0 | NA | |
147 | hsa-miR-155-5p | KLHL5 | 0.71 | 0.00687 | -0.05 | 0.79463 | miRNAWalker2 validate | -0.24 | 0 | NA | |
148 | hsa-miR-155-5p | KPNA4 | 0.71 | 0.00687 | 0.14 | 0.13709 | miRNATAP | -0.14 | 0 | NA | |
149 | hsa-miR-155-5p | LCA5 | 0.71 | 0.00687 | 0.34 | 0.04819 | MirTarget | -0.27 | 0 | NA | |
150 | hsa-miR-155-5p | LDOC1 | 0.71 | 0.00687 | -1.54 | 0 | miRNAWalker2 validate; miRTarBase | -0.3 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CELL DEVELOPMENT | 64 | 1426 | 1.264e-11 | 2.94e-08 |
2 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 74 | 1784 | 1.016e-11 | 2.94e-08 |
3 | REGULATION OF CELL DIFFERENTIATION | 65 | 1492 | 3.059e-11 | 4.744e-08 |
4 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 48 | 1004 | 8.52e-10 | 9.641e-07 |
5 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 41 | 788 | 1.45e-09 | 9.641e-07 |
6 | CIRCULATORY SYSTEM DEVELOPMENT | 41 | 788 | 1.45e-09 | 9.641e-07 |
7 | TISSUE DEVELOPMENT | 62 | 1518 | 1.25e-09 | 9.641e-07 |
8 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 51 | 1142 | 2.459e-09 | 1.43e-06 |
9 | INTRACELLULAR SIGNAL TRANSDUCTION | 62 | 1572 | 4.811e-09 | 2.487e-06 |
10 | NEUROGENESIS | 57 | 1402 | 7.684e-09 | 3.575e-06 |
11 | POSITIVE REGULATION OF GENE EXPRESSION | 65 | 1733 | 1.36e-08 | 5.014e-06 |
12 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 22 | 285 | 1.348e-08 | 5.014e-06 |
13 | MUSCLE CELL DIFFERENTIATION | 20 | 237 | 1.401e-08 | 5.014e-06 |
14 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 16 | 154 | 2.197e-08 | 7.302e-06 |
15 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 45 | 1008 | 2.404e-08 | 7.457e-06 |
16 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 43 | 957 | 4.23e-08 | 1.206e-05 |
17 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 36 | 724 | 4.926e-08 | 1.206e-05 |
18 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 62 | 1672 | 4.765e-08 | 1.206e-05 |
19 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 39 | 823 | 4.748e-08 | 1.206e-05 |
20 | REGULATION OF CELL DEVELOPMENT | 39 | 836 | 7.173e-08 | 1.669e-05 |
21 | STRIATED MUSCLE CELL DIFFERENTIATION | 16 | 173 | 1.133e-07 | 2.511e-05 |
22 | EPITHELIUM DEVELOPMENT | 41 | 945 | 2.286e-07 | 4.834e-05 |
23 | HEAD DEVELOPMENT | 34 | 709 | 2.766e-07 | 5.595e-05 |
24 | MUSCLE STRUCTURE DEVELOPMENT | 25 | 432 | 3.886e-07 | 7.534e-05 |
25 | MUSCLE CELL DEVELOPMENT | 13 | 128 | 6.05e-07 | 0.0001083 |
26 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 38 | 872 | 5.874e-07 | 0.0001083 |
27 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 62 | 1805 | 6.997e-07 | 0.0001206 |
28 | ACTIN FILAMENT BASED PROCESS | 25 | 450 | 8.245e-07 | 0.0001323 |
29 | RESPONSE TO ENDOGENOUS STIMULUS | 53 | 1450 | 8.148e-07 | 0.0001323 |
30 | EMBRYO DEVELOPMENT | 38 | 894 | 1.076e-06 | 0.0001669 |
31 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 32 | 689 | 1.259e-06 | 0.0001889 |
32 | ORGAN MORPHOGENESIS | 36 | 841 | 1.791e-06 | 0.0002525 |
33 | VASCULATURE DEVELOPMENT | 25 | 469 | 1.742e-06 | 0.0002525 |
34 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 33 | 740 | 2.066e-06 | 0.0002761 |
35 | REGULATION OF CELL PROLIFERATION | 53 | 1496 | 2.077e-06 | 0.0002761 |
36 | FOREBRAIN DEVELOPMENT | 21 | 357 | 2.602e-06 | 0.0003363 |
37 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 33 | 750 | 2.755e-06 | 0.0003465 |
38 | SKELETAL SYSTEM DEVELOPMENT | 24 | 455 | 3.374e-06 | 0.0004131 |
39 | POSITIVE REGULATION OF CELL PROLIFERATION | 34 | 814 | 5.96e-06 | 0.0007111 |
40 | RESPONSE TO GROWTH FACTOR | 24 | 475 | 6.991e-06 | 0.0008133 |
41 | PEPTIDYL TYROSINE MODIFICATION | 14 | 186 | 8.079e-06 | 0.0009063 |
42 | CELLULAR COMPONENT MORPHOGENESIS | 36 | 900 | 8.181e-06 | 0.0009063 |
43 | CELL PROJECTION ORGANIZATION | 36 | 902 | 8.588e-06 | 0.0009293 |
44 | TUBE DEVELOPMENT | 26 | 552 | 1.008e-05 | 0.001066 |
45 | NEURON DIFFERENTIATION | 35 | 874 | 1.073e-05 | 0.00111 |
46 | REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 10 | 98 | 1.164e-05 | 0.001177 |
47 | DEVELOPMENTAL GROWTH | 19 | 333 | 1.203e-05 | 0.001191 |
48 | HEART DEVELOPMENT | 23 | 466 | 1.581e-05 | 0.001533 |
49 | INOSITOL LIPID MEDIATED SIGNALING | 11 | 124 | 1.642e-05 | 0.00156 |
50 | NEGATIVE REGULATION OF GENE EXPRESSION | 50 | 1493 | 1.926e-05 | 0.001766 |
51 | POSITIVE REGULATION OF CELL DEVELOPMENT | 23 | 472 | 1.936e-05 | 0.001766 |
52 | GROWTH | 21 | 410 | 2.151e-05 | 0.001888 |
53 | POSITIVE REGULATION OF OSSIFICATION | 9 | 84 | 2.15e-05 | 0.001888 |
54 | PROTEIN PHOSPHORYLATION | 36 | 944 | 2.283e-05 | 0.001967 |
55 | MYOFIBRIL ASSEMBLY | 7 | 48 | 2.377e-05 | 0.002011 |
56 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 19 | 352 | 2.6e-05 | 0.00216 |
57 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 25 | 554 | 3.049e-05 | 0.002489 |
58 | LOCOMOTION | 40 | 1114 | 3.104e-05 | 0.002491 |
59 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 44 | 1275 | 3.161e-05 | 0.002493 |
60 | POST EMBRYONIC DEVELOPMENT | 9 | 89 | 3.429e-05 | 0.002659 |
61 | EMBRYONIC CAMERA TYPE EYE DEVELOPMENT | 6 | 35 | 3.568e-05 | 0.002722 |
62 | BLOOD VESSEL MORPHOGENESIS | 19 | 364 | 4.103e-05 | 0.003079 |
63 | CELL PROLIFERATION | 28 | 672 | 4.24e-05 | 0.003131 |
64 | MORPHOGENESIS OF AN EPITHELIUM | 20 | 400 | 4.726e-05 | 0.003436 |
65 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 57 | 1848 | 5.011e-05 | 0.003587 |
66 | NEGATIVE REGULATION OF CELL PROLIFERATION | 27 | 643 | 5.104e-05 | 0.003598 |
67 | REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 8 | 73 | 5.244e-05 | 0.003642 |
68 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 21 | 437 | 5.436e-05 | 0.003719 |
69 | CONNECTIVE TISSUE DEVELOPMENT | 13 | 194 | 5.735e-05 | 0.003867 |
70 | NEGATIVE REGULATION OF CELL DEATH | 33 | 872 | 5.882e-05 | 0.00391 |
71 | NEURON DEVELOPMENT | 28 | 687 | 6.218e-05 | 0.003968 |
72 | REPRODUCTIVE SYSTEM DEVELOPMENT | 20 | 408 | 6.217e-05 | 0.003968 |
73 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 46 | 1395 | 6.225e-05 | 0.003968 |
74 | NEURON PROJECTION DEVELOPMENT | 24 | 545 | 6.444e-05 | 0.004052 |
75 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 11 | 144 | 6.581e-05 | 0.004083 |
76 | ACTOMYOSIN STRUCTURE ORGANIZATION | 8 | 77 | 7.708e-05 | 0.004658 |
77 | REGULATION OF BMP SIGNALING PATHWAY | 8 | 77 | 7.708e-05 | 0.004658 |
78 | CARTILAGE DEVELOPMENT | 11 | 147 | 7.932e-05 | 0.004732 |
79 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 14 | 229 | 8.117e-05 | 0.004781 |
80 | NEURON PROJECTION GUIDANCE | 13 | 205 | 0.0001005 | 0.005846 |
81 | REGULATION OF GTPASE ACTIVITY | 27 | 673 | 0.0001092 | 0.006274 |
82 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 13 | 207 | 0.0001108 | 0.006288 |
83 | EPITHELIAL CELL DIFFERENTIATION | 22 | 495 | 0.0001137 | 0.006373 |
84 | TISSUE MORPHOGENESIS | 23 | 533 | 0.0001234 | 0.006758 |
85 | PHOSPHORYLATION | 41 | 1228 | 0.0001232 | 0.006758 |
86 | PALATE DEVELOPMENT | 8 | 85 | 0.0001555 | 0.008412 |
87 | MUSCLE TISSUE DEVELOPMENT | 15 | 275 | 0.0001628 | 0.008708 |
88 | SECOND MESSENGER MEDIATED SIGNALING | 11 | 160 | 0.0001688 | 0.008825 |
89 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 58 | 1977 | 0.0001672 | 0.008825 |
90 | COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION | 9 | 111 | 0.0001923 | 0.009626 |
91 | MESENCHYME DEVELOPMENT | 12 | 190 | 0.0001919 | 0.009626 |
92 | GLIAL CELL DIFFERENTIATION | 10 | 136 | 0.0001924 | 0.009626 |
93 | LENS DEVELOPMENT IN CAMERA TYPE EYE | 7 | 66 | 0.0001901 | 0.009626 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 62 | 1199 | 6.236e-14 | 5.793e-11 |
2 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 42 | 629 | 3.341e-13 | 1.552e-10 |
3 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 25 | 226 | 5.49e-13 | 1.7e-10 |
4 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 27 | 315 | 2.711e-11 | 6.296e-09 |
5 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 27 | 328 | 6.834e-11 | 1.27e-08 |
6 | REGULATORY REGION NUCLEIC ACID BINDING | 43 | 818 | 4.053e-10 | 6.276e-08 |
7 | DOUBLE STRANDED DNA BINDING | 40 | 764 | 1.958e-09 | 2.598e-07 |
8 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 25 | 371 | 2.1e-08 | 2.439e-06 |
9 | SEQUENCE SPECIFIC DNA BINDING | 45 | 1037 | 5.522e-08 | 5.7e-06 |
10 | PROTEIN TYROSINE KINASE ACTIVITY | 13 | 176 | 2.075e-05 | 0.001927 |
11 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 11 | 133 | 3.17e-05 | 0.002677 |
12 | SMAD BINDING | 8 | 72 | 4.743e-05 | 0.003637 |
13 | CHROMATIN BINDING | 21 | 435 | 5.09e-05 | 0.003637 |
14 | TRANSCRIPTION FACTOR BINDING | 23 | 524 | 9.598e-05 | 0.006369 |
15 | FIBROBLAST GROWTH FACTOR RECEPTOR BINDING | 5 | 28 | 0.0001335 | 0.00827 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 13 | 139 | 1.555e-06 | 8.086e-05 | |
2 | MAPK_signaling_pathway_hsa04010 | 15 | 295 | 0.0003461 | 0.008999 | |
3 | PI3K_Akt_signaling_pathway_hsa04151 | 15 | 352 | 0.00206 | 0.03364 | |
4 | FoxO_signaling_pathway_hsa04068 | 8 | 132 | 0.002856 | 0.03364 | |
5 | Ras_signaling_pathway_hsa04014 | 11 | 232 | 0.003556 | 0.03364 | |
6 | TGF_beta_signaling_pathway_hsa04350 | 6 | 84 | 0.00425 | 0.03364 | |
7 | Rap1_signaling_pathway_hsa04015 | 10 | 206 | 0.004529 | 0.03364 | |
8 | Adherens_junction_hsa04520 | 5 | 72 | 0.009935 | 0.062 | |
9 | Focal_adhesion_hsa04510 | 9 | 199 | 0.01073 | 0.062 | |
10 | Regulation_of_actin_cytoskeleton_hsa04810 | 9 | 208 | 0.01401 | 0.07283 | |
11 | mTOR_signaling_pathway_hsa04150 | 7 | 151 | 0.0205 | 0.09691 | |
12 | Mitophagy_animal_hsa04137 | 4 | 65 | 0.0304 | 0.1317 | |
13 | Apelin_signaling_pathway_hsa04371 | 6 | 137 | 0.03906 | 0.1562 | |
14 | ECM_receptor_interaction_hsa04512 | 4 | 82 | 0.06208 | 0.2265 | |
15 | ErbB_signaling_pathway_hsa04012 | 4 | 85 | 0.06896 | 0.2265 | |
16 | AMPK_signaling_pathway_hsa04152 | 5 | 121 | 0.06971 | 0.2265 | |
17 | Oocyte_meiosis_hsa04114 | 5 | 124 | 0.07566 | 0.2314 | |
18 | Phospholipase_D_signaling_pathway_hsa04072 | 5 | 146 | 0.1272 | 0.3675 | |
19 | Hippo_signaling_pathway_hsa04390 | 5 | 154 | 0.1491 | 0.4081 | |
20 | Gap_junction_hsa04540 | 3 | 88 | 0.2147 | 0.5582 | |
21 | Calcium_signaling_pathway_hsa04020 | 5 | 182 | 0.2362 | 0.585 | |
22 | Phosphatidylinositol_signaling_system_hsa04070 | 3 | 99 | 0.2679 | 0.5934 | |
23 | HIF_1_signaling_pathway_hsa04066 | 3 | 100 | 0.2728 | 0.5934 | |
24 | Wnt_signaling_pathway_hsa04310 | 4 | 146 | 0.2739 | 0.5934 | |
25 | Phagosome_hsa04145 | 4 | 152 | 0.2982 | 0.6202 | |
26 | TNF_signaling_pathway_hsa04668 | 3 | 108 | 0.3124 | 0.6248 | |
27 | cGMP_PKG_signaling_pathway_hsa04022 | 4 | 163 | 0.3433 | 0.6511 | |
28 | p53_signaling_pathway_hsa04115 | 2 | 68 | 0.3506 | 0.6511 | |
29 | Cell_cycle_hsa04110 | 3 | 124 | 0.3916 | 0.6916 | |
30 | Autophagy_animal_hsa04140 | 3 | 128 | 0.4111 | 0.6916 | |
31 | Endocytosis_hsa04144 | 5 | 244 | 0.4555 | 0.7178 | |
32 | cAMP_signaling_pathway_hsa04024 | 4 | 198 | 0.4852 | 0.7303 | |
33 | Cell_adhesion_molecules_.CAMs._hsa04514 | 3 | 145 | 0.4915 | 0.7303 | |
34 | Cellular_senescence_hsa04218 | 3 | 160 | 0.5577 | 0.7804 | |
35 | Jak_STAT_signaling_pathway_hsa04630 | 3 | 162 | 0.5661 | 0.7804 | |
36 | Cytokine_cytokine_receptor_interaction_hsa04060 | 4 | 270 | 0.7251 | 0.9427 | |
37 | Tight_junction_hsa04530 | 2 | 170 | 0.8172 | 0.9979 | |
38 | Neuroactive_ligand_receptor_interaction_hsa04080 | 3 | 278 | 0.8831 | 1 |